Investor Presentaiton
VERSALIS
LONG TERM VALUE THROUGH RESTRUCTURING & NEW PLATFORMS
HIGH CAPITAL INTENSITY
HIGH SCALE
HIGH MARGIN VOLATILITY
RESTRUCTURING
BASE CHEMICALS
PERIMETER REDUCTION &
EBITDA BREAKEVEN
IN 2025
SITE RECONFIGURATION
CIRCULARITY INVESTMENTS
THROUGH COMPLEMENTARY
SOLUTIONS
EBIT POSITIVE
IN 2026
30
versalis
LOW CAPITAL INTENSITY
LOW SCALE
LOW MARGIN VOLATILITY
FCF BREAKEVEN
IN 2027
STRONG SPECIALISATION
& PARTICIPATION IN
HIGH-END MARKETS
LEADERSHIP IN
BIOCHEMISTRY
REDUCED CAPEX
<300 € MLN/Y AVG 2024-2027
STRONG EFFICIENCY
AND COST REDUCTION
TRANSFORMING - NEW PLATFORMS GROWTH
BIOCHEMICALS & ADVANCED MATERIALS
RESTRUCTURING TARGET OVER THE PLAN OF € 150-300 MLN /Y BASED ON SCENARIO
NEW PLATFORMS SIZE MORE THAN DOUBLE IN 2027 VS 2023View entire presentation